期刊
IMMUNOTHERAPY
卷 3, 期 4, 页码 517-537出版社
FUTURE MEDICINE LTD
DOI: 10.2217/IMT.11.10
关键词
chimeric antigen receptor; immune suppression; immune therapy; MDSC; pancreatic cancer; T cell; Treg; vaccine
类别
资金
- American Cancer Society
- NIH [1R21CA150945-01]
Pancreatic adenocarcinoma is the fourth leading cause of cancer death with an overall 5-year survival of less than 5%. As there is ample evidence that pancreatic adenocarcinomas elicit antitumor immune responses, identification of pancreatic cancer-associated antigens has spurred the development of vaccination-based strategies for treatment. While promising results have been observed in animal tumor models, most clinical studies have found only limited success. As most trials were performed in patients with advanced pancreatic cancer, the contribution of immune suppressor mechanisms should be taken into account. In this article, we detail recent work in tumor antigen vaccination and the recently identified mechanisms of immune suppression in pancreatic cancer. We offer our perspective on how to increase the clinical efficacy of vaccines for pancreatic cancer.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据